

HETEROCYCLES, Vol. 104, No. 7, 2022, pp. 1315 - 1322. © 2022 The Japan Institute of Heterocyclic Chemistry  
Received, 10th April, 2022, Accepted, 11th May, 2022, Published online, 16th May, 2022  
DOI: 10.3987/COM-22-14669

**ANTIMICROBIAL ACETOPHENONE AND PHENALENONE  
DERIVATIVES FROM A SOIL-DERIVED FUNGUS *PENICILLIUM  
VERRUCISPORUM* JX1**

**Huiping Hu,<sup>1#</sup> Yuting Tang,<sup>2#</sup> Hengyi Lin,<sup>3</sup> Zheng Ma,<sup>3</sup> Penglai Fan,<sup>4,5</sup>  
Xiachang Wang,<sup>6</sup> Yongyong Zhang,<sup>1\*</sup> and Jiarong Pan<sup>1\*</sup>**


<sup>1</sup>Key Laboratory of Marine Food Quality and Hazard Controlling Technology of Zhejiang Province, College of Life Sciences, China Jiliang University, Hangzhou 310018, China; <sup>2</sup>State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China; <sup>3</sup>Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China; <sup>4</sup>Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection (Guangxi Normal University), Ministry of Education, Guilin 541000, China; <sup>5</sup>Guangxi Key Laboratory of Rare and Endangered Animal Ecology, College of Life Sciences, Guangxi Normal University, Guilin 541000, China; <sup>6</sup>Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. E-mail: zhangyy76@163.com; panjr@cjlu.edu.cn

#These authors contributed equally to this work.

**Abstract** – A new acetophenone derivative, named veracetophenone (**1**), along with six known compounds communol F (**2**), clavatul (**3**), (+)-scleroquinone (**4**), (–)-tryptelone (**5**), (–)-sclerodin (**6**), and (–)-scleroderolide (**7**), were isolated from a soil-derived fungus *Penicillium verrucisporum* JX1. Their structures were identified on the basis of spectral analysis of 1D, 2D-NMR, and HRESIMS. The configuration of **4** was depicted based on spectroscopic data as well as optical property. Their antibacterial and antifungal activities were also evaluated.

Natural products or natural product-derived compounds, nowadays, still play an important role in drug discovery.<sup>1,2</sup> As fungus is a prolific producer of natural products with a broad diversity of skeletons and

bioactivities, many attentions were refocused on it after the finding and activation of biosynthetic gene clusters in fungal genome.<sup>3,4</sup> During our ongoing investigation of active scaffolds, a soil-derived fungus, *Penicillium verrucisporum* JX1, attracted our attention owing to its antimicrobial activity during the preliminary screening tests. In order to discover the bioactive constituents, a scale-up fermentation (12 L) of strain JX1 was performed, followed by extraction and separation, to yield a new acetophenone derivative (**1**), together with two known acetophenone derivatives communol F (**2**) and clavatul (**3**) as well as four known phenalenone derivatives (+)-scleroquinone (**4**), (-)-tryptelone (**5**), (-)-sclerodin (**6**), and (-)-scleroderolide (**7**) (Figure 1). Antimicrobial bioassays indicated their potential antibacterial and antifungal activities, which were coincident with the literature.<sup>5</sup> This study also highlights the first reported antifungal activity of communol F<sup>6</sup> (**2**) and antimicrobial activity of (+)-scleroquinone (**4**). In this paper, the isolation, structural identification, and biological tests of these compounds were described.



**Figure 1.** Chemical structures of compounds **1-7**

Compound **1** had the molecular formula of C<sub>13</sub>H<sub>18</sub>O<sub>4</sub> on the basis of the HRESIMS data at  $m/z$  237.1131 [M - H]<sup>-</sup> (calcd for 237.1121, C<sub>13</sub>H<sub>17</sub>O<sub>4</sub>). The <sup>13</sup>C and <sup>1</sup>H NMR data (Table 1) of **1** were very similar with those of clavatul (**3**), with the presence of the additional signals for an oxygenated methine ( $\delta_C$  65.5/ $\delta_H$  3.51) and two methylenes ( $\delta_C$  37.8/ $\delta_H$  1.48 and  $\delta_C$  18.8/ $\delta_H$  2.54, 2.63) in **1** based on the analysis of <sup>1</sup>H, <sup>13</sup>C NMR and HSQC spectra. Further investigations on the 2D NMR spectra, including the COSY cross peaks of H<sub>2</sub>-9 ( $\delta_H$  2.54, 2.63)/H<sub>2</sub>-10 ( $\delta_H$  1.48), H<sub>2</sub>-10/H-11 ( $\delta_H$  3.51), and H-11/H<sub>3</sub>-12 ( $\delta_H$  1.06), and the HMBC correlations of H<sub>2</sub>-9, H<sub>2</sub>-10 and H<sub>3</sub>-12 with C-11 ( $\delta_C$  65.5), H<sub>3</sub>-12, H-11, and H<sub>2</sub>-9 with C-10 ( $\delta_C$  37.8), as well as H-11 and H<sub>2</sub>-10 with C-9 ( $\delta_C$  18.8), suggested a 3-hydroxybutyl substituent in **1** (Figure 2). And it was connected to C-5 ( $\delta_C$  114.7) based on HMBC correlations from H<sub>2</sub>-9 and H<sub>2</sub>-10 to C-5. A downfield hydroxyl group ( $\delta_H$  12.99) correlated with C-3 ( $\delta_C$  111.3), C-4 ( $\delta_C$  160.7), and C-5 in HMBC spectrum was thereby determined to be attached at C-4. Similarly, a methyl group ( $\delta_C$  16.3/ $\delta_H$  2.10) was deduced to be sited at C-7 ( $\delta_C$  116.5) based on its HMBC correlations with C-7, C-8 ( $\delta_C$  130.3). The unassigned carbon signal ( $\delta_C$  162.8) was confirmed as C-6 by HMBC correlation with H-8 ( $\delta_H$  7.48). H-8 was correlated with C-2 ( $\delta_C$  202.1), C-13 ( $\delta_C$  16.3), and C-4 as well. It was apparent that the ketone group [a keto ( $\delta_C$  202.1)

and a methyl group ( $\delta_C$  26.0/ $\delta_H$  2.49)] was linked to C-3 according to the HMBC correlations of H<sub>3</sub>-1 ( $\delta_H$  2.49) with C-2 and C-3. Hence, the structure of compound **1** was elucidated and named as veracetophenone (Figure 1).


**Table 1.** <sup>13</sup>C and <sup>1</sup>H NMR spectroscopic data of compounds **1** and **4**

Positio n	<b>1</b> <sup>a)</sup>			<b>4</b>			
	$\delta_C$	type	$\delta_H$ (mult., <i>J</i> in Hz)	$\delta_C$ <sup>b)</sup>	type	$\delta_H$ <sup>b)</sup> (mult., <i>J</i> in Hz)	$\delta_H$ <sup>c)</sup> (mult., <i>J</i> in Hz)
1	26.0	Me	2.49 (s)	163.2	C		
2	202.1	C		126.0	CH	6.82 (s)	6.97 (s)
3	111.3	C		143.5	C		
4	160.7	C		115.2	C		
5	114.7	C		131.8	C		
6	162.8 <sup>d)</sup>	C		126.6	C		
7	116.5	C		184.1	C		
8	130.3	CH	7.48 (s)	175.4	C		
9	18.8	CH <sub>2</sub>	2.54 (m); 2.63 (m)	122.1	C		
10	37.8	CH <sub>2</sub>	1.48 (m)	175.6	C		
11	65.5	CH	3.51 (m)	43.8	C		
12	23.3	Me	1.06 (d, 6.1)	94.4	CH	4.72 (q, 6.6)	4.63 (q, 6.7)
13	16.3	Me	2.10 (s)	22.7	Me	2.54 (s)	2.58 (s)
14				170.6	C		
15				20.5	Me	1.23 (s)	1.25 (s)
16				25.9	Me	1.40 (s)	1.42 (s)
17				14.9	Me	1.48 (d, 6.7)	1.44 (d, 6.6)
18				53.1	Me	3.90 (s)	3.87 (s)
OH			12.99 (s)				

a) Measured in DMSO-*d*<sub>6</sub> at 125 MHz (<sup>13</sup>C) and 500 MHz (<sup>1</sup>H); b) Measured in CD<sub>3</sub>OD at 200 MHz (<sup>13</sup>C) and 800 MHz (<sup>1</sup>H); c) Measured in CDCl<sub>3</sub> at 500 MHz (<sup>1</sup>H); d) deduced by HMBC correlations

Compound **4** displayed a quasimolecular ion at *m/z* 353.0993 [M + Na]<sup>+</sup> (calcd for 353.0996, C<sub>18</sub>H<sub>18</sub>O<sub>6</sub>Na) in the HRESIMS, consistent with the molecular formula C<sub>18</sub>H<sub>18</sub>O<sub>6</sub>. Analysis of 1D, 2D NMR (Figure 2) as well as HRESIMS and EIMS spectra of compound **4** helped to determine the structure as scleroquinone,<sup>7</sup> whose carbon data and optical value were not reported yet. Hence, the carbon chemical shifts of compound **4** were assigned for the first time (Table 1). The stereochemistry at C-12 could be deduced as *R*-configuration on the basis of its optical value of + 156.5, due to the right rotation of such frameworks was in *R*-configuration and *vice versa*.<sup>8-13</sup> The configuration of compound **4** was thus depicted and named as (+)-scleroquinone (Figure 1).

Five other known compounds were identified as communol F (**2**),<sup>6</sup> clavatul (**3**),<sup>14</sup> (–)-tryptelone (**5**),<sup>12</sup> (–)-sclerodin (**6**),<sup>15</sup> and (–)-scleroderolide (**7**),<sup>13</sup> respectively, by comparison with MS and NMR data reported in the literatures.



**Figure 2.**  $^1\text{H}$ - $^1\text{H}$  COSY and key HMBC correlations for compounds **1** and **4**

The biological activity tests *in vitro* were performed using two bacterial strains, *Bacillus subtilis* (Gram-positive) and *Escherichia coli* (Gram-negative), and a fungus strain of *Saccharomyces cerevisiae* (Table 2). Compound **1** showed moderate inhibitory effect on *B. subtilis* (MIC: 64  $\mu\text{g}/\text{mL}$ ). Compound **2** displayed apparent inhibition against both *B. subtilis* and *S. cerevisiae* with the same MIC value of 16  $\mu\text{g}/\text{mL}$ , as well as moderate inhibition against *E. coli* (MIC: 64  $\mu\text{g}/\text{mL}$ ). From the point of view of structure-activity relationship, the aldehyde group in **2** might be the key substituent for the antibacterial and antifungal bioactivity. Moreover, compound **4** was firstly reported its moderate inhibition against all three tested strains.

**Table 2.** *In vitro* antimicrobial activities of compounds **1-7** (MIC:  $\mu\text{g}/\text{mL}$ )

Compound	Test microorganisms		
	<i>B. subtilis</i>	<i>E. coli</i>	<i>S. cerevisiae</i>
<b>1</b>	64	>256	>256
<b>2</b>	16	64	16
<b>3</b>	32	128	128
<b>4</b>	64	128	32
<b>5</b>	128	>256	64
<b>6</b>	64	>256	128
<b>7</b>	32	128	64
Gentamicin	1	2	-
Amphotericin B	-	-	2

## EXPERIMENTAL

### General Experimental Procedures

Optical rotation was obtained using a Rudolph Research Autopol III automatic polarimeter. UV spectra were measured with a Shimadzu 2401A spectrophotometer. 1D and 2D NMR spectra were recorded on Bruker AVANCE AV500 and Bruker AVANCE 800 AV spectrometer with SiMe<sub>4</sub> as internal standard. Liquid chromatography-mass spectrometry (LC-MS) was conducted with an Agilent 6120 Quadrupole MSD mass spectrometer. EIMS was recorded on a QP2010 mass spectrometer. High resolution electrospray mass (HRESIMS) data were performed with an Agilent Technologies 6210 LC/TOF mass spectrometer. Preparative HPLC was performed on a Shimadzu LC-6AD equipped with PDA detector and a Develosil ODS-HG Column (10.0 × 250 mm, 5 μm). Column chromatography (CC) was carried out on silica gel H (100-200 and 200-300 mesh, Qingdao Marine Chemical Ltd.), Gel ODS-A (50 μm, YMC), and Sephadex LH-20 (25-100 μm, Pharmacia). *Bacillus subtilis* (CGMCC 1.9086), *Escherichia coli* (CGMCC 1.8745) and *Saccharomyces cerevisiae* (CGMCC 2.3888) were purchased from China General Microbiological Culture Collection Center.

### Fungal material

Strain JX1 was isolated from a soil sample collected from Jingxi conservation of Guangxi (Coordinates: N 22° 53' 29.58" and E 106° 29' 39.81"). Strain isolation procedure was mainly followed the reported protocol.<sup>16</sup> A soil sample was kept at 75 °C for 10 min to restrict nonsporulating bacteria. Serial dilutions (10<sup>-1</sup>, 10<sup>-2</sup>, 10<sup>-3</sup>) were prepared from adding 0.5 g of soil in 1.0 mL of sterile water. A 100 μL aliquot was spread on M2 agar (glucose, 4.0 g/L; malt extract, 10.0 g/L; yeast extract, 4.0 g/L; CaCO<sub>3</sub>, 2.0 g/L; and agar, 15.0 g/L) plates with nalidixic acid (75 μg/mL). After incubation for 3-7 days at 28 °C, a number of colonies were observed on media plates, which were purified by subculturing on the M2 agar plates for several times. Strain JX1 was displayed 99.6% identity as *Penicillium verrucisporum* based on its morphological characteristics and ITS gene sequences (see Supporting Information, Figure S1. GenBank Accession No. MZ914656). A voucher strain has been deposited in our laboratory at -80 °C.

### Fermentation, Extraction and Isolation

Strain JX1 was cultivated on M2 agar plates at 28 °C for 4 days. To prepare the seed culture, chunks of agar with the fully-grown strain were used to inoculate six 250 mL conical flasks, each containing 50 mL of medium Bran (corn flour, 40.0 g/L; glucose, 10.0 g/L; gluten powder, 5.0 g/L; K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, 0.5 g/L; bran, 10.0 g/L; CaCO<sub>3</sub>, 2.0 g/L; and (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1.0 g/L).<sup>17</sup> After 3 days of incubation (200 rpm, 28 °C), the seed cultures were transferred to inoculate 120 flasks (250 mL) containing 100 mL of medium Bran on a rotary shaker (200 rpm, 28 °C) for 7 days. The fermented whole broth (12 L) was centrifuged (8000 rpm, 15 min) at 4 °C and filtered through gauze to obtain filtrate and mycelia. The filtrate was subjected to a XAD-16N resin column (6 × 50 cm) and washed with water (5 L) and MeOH (5 L) successively. The

MeOH fraction was evaporated under reduced pressure to give 8.8 g of crude extract. The mycelia were extracted with MeOH (3 × 5 L) using sonication for 30 min. The MeOH solution was then evaporated to yield 27.8 g of crude extract. Both crude extracts were combined according to similar characters of main metabolites on the basis of HPLC and TLC analyses.

The combined crude extract (36.6 g) was subjected to a silica gel column (5 × 70 cm, 100–200 mesh) with a gradient elution of petroleum ether-EtOAc (9:1, 8:2, 7:3, 6:4 and 5:5; each 3 L) to afford five fractions (A-E) based on TLC analyses. Fraction A (19.7 g) was rechromatographed on a silica gel column (4 × 60 cm, 200-300 mesh) eluted with petroleum ether-EtOAc (95:5; 8 L) to give six subfractions (A1-A6). By recrystallization in EtOAc, subfractions A1, A2, and A4 yielded compounds **6** (832 mg), **2** (6.3 mg), and **3** (15.7 mg), respectively. Fraction B (2.2 g) was separated on a Sephadex LH-20 column (2 × 120 cm) eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (1:1) to give Fr. B1-B5. Subfraction B2 (267 mg) was further divided into six parts (Fr. B2-1-B2-6) using an ODS column (2.5 × 30 cm) elution with 90% aqueous MeOH. Fr. B2-2 (88 mg) was purified by semipreparative HPLC using 40% aqueous MeCN as eluant to yield compound **1** (3.7 mg). Similarly, fraction D (2.6 g) was first purified by a Sephadex LH-20 [CH<sub>2</sub>Cl<sub>2</sub>-MeOH (1:1)], and then loaded onto an ODS column (80% aqueous MeOH), and subsequently prepared using semipreparative HPLC (35% aqueous MeCN) to yield compounds **4** (1.3 mg), **5** (2.1 mg), and **7** (12.1 mg).

Compound **1**: pale powder;  $[\alpha]_D^{25} + 6.1$  (*c* 0.2, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ): 218 (4.33), 283 (4.17), 330 (3.79) nm; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz), see Table 1; (+)-ESIMS *m/z*: 239.2 [M + H]<sup>+</sup>, 261.2 [M + Na]<sup>+</sup>; (-)-ESIMS *m/z*: 237.2 [M - H]<sup>-</sup>; (-)-HRESIMS *m/z*: 237.1131 [M - H]<sup>-</sup> (calcd for 237.1121, C<sub>13</sub>H<sub>17</sub>O<sub>4</sub>).

### Antimicrobial activity assays

Two bacterial strains, *Bacillus subtilis* (Gram-positive) and *Escherichia coli* (Gram-negative), and a fungus strain of *Saccharomyces cerevisiae* were carried out as model strains for biological activity according to the method<sup>18</sup> with minor adjustment. Bacterial strains and fungus strain were grown in liquid or on agar plates using LB medium (yeast extract, 5 g/L; peptone, 10 g/L; and NaCl 10 g/L) and YPDA medium (yeast extract, 10.0 g/L; peptone, 20.0 g/L; glucose, 20.0 g/L; and adenine sulfate, 0.03 g/L), respectively. Individual stains were grown in 5 mL of medium for 16 h at 37 °C with shaking (200 rpm). And then, the liquid cultures were diluted using homologous sterile liquid medium until OD<sub>600</sub> 0.02 by calculation. Aliquots (200 μL) of each diluted culture were subsequently transferred into the individual well of a 96-well plate supplied with 2 μL of the samples dissolved in DMSO (final concentration range from 256 μg/mL to 2 μg/mL). After incubated at 37 °C for 16 h with shaking (200 rpm), the OD<sub>600</sub> of each well was recorded whose value was normalized to the negative control (1% DMSO). Finally, a 5 μL aliquot of resazurin solution was added to each well and the plates were then incubated at 37 °C for another 3 h with shaking (200 rpm) to allow resazurin to convert to resorufin by viable cells. The minimal concentration of the test

compound that inhibited visible microbial growth was defined as the MIC value. Commercial gentamicin and amphotericin B were set as the positive controls for bacteria and fungus, respectively.

## ACKNOWLEDGEMENTS

This research was supported by Zhejiang Provincial Natural Science Foundation of China (LY20C140006), the National Natural Science Foundation of China (31972320), and Jiangsu Provincial Innovation and Entrepreneurship Talent Plan (202010528).

## REFERENCES

1. S. Stone, D. J. Newman, S. L. Colletti, and D. S. Tan, [Nat. Prod. Rep.](#), 2022, **39**, 20.
2. M. S. Butler, A. A. Robertson, and M. A. Cooper, [Nat. Prod. Rep.](#), 2014, **31**, 1612.
3. N. P. Keller, [Nat. Rev. Microbiol.](#), 2019, **17**, 167.
4. T. Hautbergue, E. L. Jamin, L. Debrauwer, O. Puel, and I. P. Oswald, [Nat. Prod. Rep.](#), 2018, **35**, 147.
5. M. F. Elsebai, M. Saleem, M. V. Tejesvi, M. Kajula, S. Mattila, M. Mehiri, A. Turpeinen, and A. M. Pirttila, [Nat. Prod. Rep.](#), 2014, **31**, 628.
6. J. F. Wang, P. P. Liu, Y. Wang, H. Wang, J. Li, Y. B. Zhuang, and W. M. Zhu, [Chin. J. Chem.](#), 2012, **30**, 1236.
7. W. A. Ayer, M. Kamada, and Y. T. Ma, [Can. J. Chem.](#), 1989, **67**, 2089.
8. Q. Li, R. Y. Zhu, W. W. Yi, W. Y. Chai, Z. Z. Zhang, and X. Y. Lian, [Phytochemistry](#), 2018, **152**, 53.
9. R. G. Cooke, E. L. Ghisalberti, B. L. Johnson, C. L. Raston, B. W. Skelton, and A. H. White, [Aust. J. Chem.](#), 2006, **59**, 925.
10. A. P. G. Macabeo, L. A. E. Pilapil, K. Y. M. Garcia, M. T. J. Quimque, C. Phukhamsakda, A. J. C. Cruz, K. D. Hyde, and M. Stadler, [Molecules](#), 2020, **25**, 965.
11. C. Intaraudom, S. Nitthithanasilp, P. Rachtawee, T. Boonruangprapa, S. Prabpai, P. Kongsaree, and P. Pittayakhajonwut, [Phytochemistry](#), 2015, **120**, 19.
12. M. F. Elsebai, L. Natesan, S. Kehraus, I. E. Mohamed, G. Schnakenburg, F. Sasse, S. Shaaban, M. Gutschow, and G. M. Konig, [J. Nat. Prod.](#), 2011, **74**, 2282.
13. N. Tabata, H. Tomoda, and S. Omura, [J. Antibiot.](#), 1998, **51**, 624.
14. L. Astudillo, G. Schmeda-Hirschmann, R. Soto, C. Sandoval, C. Afonso, M. J. Gonzalez, and A. Kijjoo, [World J. Microbiol. Biotechnol.](#), 2000, **16**, 585.
15. W. A. Ayer, Y. Hoyano, M. S. Pedras, and I. V. Altena, [Can. J. Chem.](#), 1986, **64**, 1585.
16. X. C. Wang, K. A. Shaaban, S. I. Elshahawi, L. V. Ponomareva, M. Sunkara, Y. N. Zhang, G. C. Copley, J. C. Hower, A. J. Morris, M. K. Kharel, and J. S. Thorson, [J. Nat. Prod.](#), 2013, **76**, 1441.

17. H. M. Zhao, A. P. Yang, N. Zhang, S. Y. Li, T. J. Yuan, N. Ding, S. W. Zhang, S. Bao, C. Wang, Y. N. Zhang, X. C. Wang, and L. H. Hu, [\*J. Agric. Food Chem.\*, 2020, \*\*68\*\*, 1588.](#)
18. Z. Cui, X. C. Wang, S. Koppermann, J. S. Thorson, C. Ducho, and S. G. Van Lanen, [\*J. Nat. Prod.\*, 2018, \*\*81\*\*, 942.](#)